Shenzhen YHLO Biotech Co LtdSHG 688575 Stock Report

Shenzhen YHLO Biotech Co., Ltd. engages in the research and development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay solution for diagnosis of autoimmune diseases, reproductive health, and infectious diseases. The company is headquartered in Shenzhen, Guangdong and currently employs 1,393 full-time employees. The company went IPO on 2021-05-17. The firm's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The firm's main products include in-vitro diagnostic instruments and supporting reagents based on chemiluminescence, immunoblotting, enzyme-linked immunoassay, immunofluorescence chromatography and other methodologies. The firm distributes its products in domestic market and to overseas markets.